RECRUITING

Disulfiram for Treatment of Retinal Degeneration

Talk to us

Conditions

Inherited Retinal Dystrophy Primarily Involving Sensory Retina

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Aberrant retinoic acid signaling driven by the degenerating outer retina leads to pathological changes to the inner retina. The resulting hyperactivity of retinal ganglion cells leads to further diminution of the remaining vision in those afflicted with inherited retinal diseases. Inhibition of this pathway has led to improved visual function in murine models of retinal degeneration. This can be accomplished in humans with the FDA-approved irreversible inhibitor of aldehyde dehydrogenases, disulfiram.

Official Title

A Cross-over Randomized Control Trial to Evaluate the Retinaldehyde Dehydrogenase Inhibitor, Disulfiram, in Improving Retinal Sensitivity in Eyes Affected by Inherited Retinal Degeneration

Quick Facts

Study Start:2025-01-03
Study Completion:2025-11-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05626920

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Best corrected ETDRS visual acuity letter score ≥ 70 (i.e., 20/40 or better) within 30 days of enrollment.
  2. * Goldmann visual field exhibiting constriction of visual fields to 10 degrees centrally
  3. * Able and willing to provide informed consent
  4. * Willing and able to abstain from alcohol consumption for the duration of the study and the 2 weeks preceding it and 2 weeks following the study end point
  5. * Alanine transaminase (ALT): less than 40 IU/L
  6. * Aspartate transaminase (AST): less than 40 IU/L
  7. * Alkaline phosphatase (ALP): less than 300 IU/L
  8. * Albumin (Alb): less than 50 g/L
  9. * Total Protein: less than 80 g/L
  10. * Total Bilirubin: less than 30 umol/L
  1. * A condition that, in the opinion of the investigator, would preclude participation in the study, e.g., alcohol dependence, cardiovascular disease, hepatitis.
  2. * Individuals with a history of diabetes mellitus
  3. * Individuals with a history of psychosis
  4. * Individuals with hypothyroidism
  5. * Individuals with hypersensitivity to thiuram derivatives causing rubber contact dermatitis
  6. * Those on anticoagulant therapy or other medications that may be affected by disulfiram.
  7. * An ocular condition, other than inherited retinal degeneration, is present such that, in the opinion of the investigator, visual acuity might be affected (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, non-retinal conditions such as epiretinal membrane or vitreo-macular traction, vein occlusion, uveitis or other ocular inflammatory diseases such as neovascular glaucoma, etc).
  8. * History of major ocular surgery within the prior 6 months or major ocular surgery anticipated within the next 6 months following randomization.
  9. * Exam evidence of severe external ocular infection, including conjunctivitis, chalazion, or substantial blepharitis
  10. * Participation in an investigational trial that involves treatment with any drug within 30 days of randomization that has not received regulatory approval at the time of study entry.
  11. * Known allergy or hypersensitivity to any component of the study drug.
  12. * For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months. Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment will be used to determine when a pregnancy test is needed.
  13. * Participants who expect to move out of the area of the clinical center during the 8 months of the study

Contacts and Locations

Study Contact

Debarshi Mustafi, MD, PhD
CONTACT
206-616-9305
debarshi@uw.edu

Principal Investigator

Debarshi Mustafi, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Washington

Study Locations (Sites)

University of Washington-South Lake Union Retina Center
Seattle, Washington, 98109
United States

Collaborators and Investigators

Sponsor: University of Washington

  • Debarshi Mustafi, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Washington

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-03
Study Completion Date2025-11-01

Study Record Updates

Study Start Date2025-01-03
Study Completion Date2025-11-01

Terms related to this study

Additional Relevant MeSH Terms

  • Inherited Retinal Dystrophy Primarily Involving Sensory Retina